CORE--CLINICAL

临床核心的主要目标是在ADRC维持一个由375-400名志愿者患者和对照组组成的小组，并在Chula Vista的卫星诊所维持100名志愿者患者和对照组，作为我们西班牙裔倡议的一部分，并招募新的轻度认知障碍的D受试者(定义为DRS >09，其中许多人将离开MMSE bbb24 /30，以取代受损更严重的受试者。在这一竞争性更新期间，我们将增加对特定患者组和对照组的招募，以满足研究需求。特别强调的是招募80岁以上的对照组，以满足对老年对照脑进行更多临床病理相关性解剖的需要，满足对老年对照脑进行更多临床病理相关性解剖的需要，以及满足那些研究遗传标记的需要（因为载脂蛋白eepsilon4作为阿尔茨海默病的主要易感因子的作用在80岁后减弱）。年度参与者评估将包括人口、历史、医学、神经学、精神病学和神经心理学检查，以帮助诊断并跟踪认知和神经学进展的年度变化。这些评估提供了一个行为数据库，可用于与ADRC相关的各种研究项目，此外，还提供了有关AD病程和进展的详细纵向数据。临床中心保存成纤维细胞培养物、DNA、血浆样本和脑脊液，供各种研究人员使用。临床核心提供了允许参与多中心试验、合作数据和基因分析的资源，并为圣地亚哥的其他D研究人员提供了一个良好的特征队列。最后，将开展发展工作，以提高我们早期诊断AD的能力，并提高其他痴呆的诊断，如与Lew体相关的痴呆和额颞叶痴呆。

The principle objective of the Clinical Core will be to maintain a panel of 375-400 volunteer patients and controls at the ADRC, and 100 volunteer patients & controls as part of our Hispanic initiative at our satellite clinic in Chula Vista, and to recruit new D subjects with a mild degree of cognitive impairment (defined as DRS>109, many of whom will leave MMSE >24/30 to replace subjects who have become more impaired. During the period of this competing renewal we will increase our recruitment of specific groups of patients and controls to meet research needs. Particular emphasis will be to recruit controls over the age of 80 in order to meet the need for a greater number of autopsies of elderly control brains for clinical-pathological correlations and to meet for a greater number of autopsies of elderly control brains for clinical-pathological correlations and to meet the needs of those studying genetic markers (since the effect of Apo-Eepsilon4 as the major susceptibility factor for AD diminishes after age 80). Annual participant evaluations will include demographic, historical, medical, neurological, psychiatric and neuropsychological examinations to aid in diagnosis and to track yearly changes in cognitive and neurological progression. The evaluations provide a behavioral data base that can be used by the various research projects associated with the ADRC and in addition, provide detailed longitudinal data on the course and progression of AD. The Clinical Core maintains banks of fibroblast cultures, DNA, plasma samples, and CSF that are used by a variety of investigators. The Clinical Core provides the sources that permits participation multicenter trials and collaboration data and genetic analysis, as well as supply a well characterized cohort to other D investigators in San Diego. Finally, developmental work will be undertaken to improve our ability to diagnose AD early and to improve the diagnosis of other dementias such as dementia associated with Lew bodies and fronto-temporal dementia.